Acceleron Pharma Science & Pipeline

Science & Pipeline

Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis.

Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling.


Hematology

Hematology

REBLOZYL®
(luspatercept-aamt)

PreclinicalPre Phase 1Ph1 Phase 2Ph2 Phase 3Ph3 ApprovedApp
REBLOZYL® (luspatercept-aamt)
Beta-Thalassemia

transfusion dependent

Beta-Thalassemia

transfusion dependent

luspatercept-aamt
luspatercept-aamt

Beta-Thalassemia

non-transfusion dependent

Beta-Thalassemia

non-transfusion dependent

BEYOND Trial*BEYOND Trial*
Myelodysplastic Syndromes
Myelodysplastic
Syndromes
MEDALIST Trial*MEDALIST Trial*
COMMANDS Trial*COMMANDS Trial*
Myelofibrosis
Myelofibrosis
Ph2 Trial*Ph 2*

* Bristol-Myers Squibb-sponsored